Transfidelity
@Transfidelity_
Followers
247
Following
609
Media
30
Statuses
181
Transfidelity aims to enhance the accuracy of protein synthesis to prevent the misfolding and aggregation associated with neurodegenerative diseases.
Joined May 2025
$FIDEL is now fully live on @Molecule_dao! 🔗 https://t.co/lr5P5sYt1Z This enables the public to trade and track the token, as well as verify our team's progress as we advance the project.📈 #DeSci #ENDALZ #Neuroscience
$FIDEL is now live on Molecule. A novel Alzheimer's project from top-tier researchers, now tradable. Supported by DeSci leaders @Cerebrum_DAO, @vita_dao, @beakerdao and more... Track token performance, explore the science, and follow the journey: https://t.co/QE4mbiDAUu
10
9
32
Here is Dr. Dimitri Scherbakov and his wonderful little friends (HEK293 cells) together, preparing for the new experiment! Stay tuned for the next results!
1
0
10
Amazing work on this project from the @NEURONGale team.
A phenomenal response from the community to surge past the initial $50,000 goal and hit 3x plus within such a short space of time! 🚀🚀🚀
0
1
4
Less than 1 hour to go before the @NEURONGale launch with @BioProtocol! We've assembled an AAA team to test a potent galectin-3 inhibitor in an Alzheimer's mouse model.
Less than 2 hours until the first Ignition Sale on Bio Season 2, @NEURONGale. Here’s everything you need to know 🧵↓
19
4
52
Dr. Dimitri Scherbakov: "Results obtained are encouraging and scientifically compelling. Recent data reveal additional perspectives and new potential therapeutic targets. The picture is becoming more complex—however balanced and scientifically intriguing!"
0
0
5
The two hit compounds we identified are known molecules being repositioned for translation fidelity. Current work: understanding which pathways they modulate. This will guide discovery of novel optimized compounds. Results so far are encouraging.
1
1
4
IRB approval is nearly complete. Infrastructure operational. Partnerships finalized. The first-ever double-blind, placebo-controlled, decentralized trial for a brain health supplement, @Neuron_Percepta, starts soon! A colossal milestone for #DeSci.
VERY EXCITING NEWS. The Percepta clinical trial infrastructure is complete, with all necessary partnerships secured. This will be the first tokenized brain health supplement to reach double-blind placebo-controlled human trials. Recruitment is starting soon. A huge milestone.
10
2
26
Research from Dr. Luis Rios and his team reveals a precise target on Drp1 to stop mitochondrial damage without disrupting healthy cell activity. A huge step toward safer therapies for mitochondrial dysfunction.
Dr. Luis Rios identified the exact binding site where small molecules can block harmful Drp1-Fis1 interactions. The "SWAG" binding site offers a precise target for drugs that prevent mitochondrial damage without affecting normal cellular processes. Ref: https://t.co/gBDqCDsfnG
5
7
26
Dr. Luis Rios identified the exact binding site where small molecules can block harmful Drp1-Fis1 interactions. The "SWAG" binding site offers a precise target for drugs that prevent mitochondrial damage without affecting normal cellular processes. Ref: https://t.co/gBDqCDsfnG
0
2
5
Next milestone: finding analogs of the two hit compounds and understanding their mechanism of action.
0
0
1
Of 2,400 molecules screened, we identified two that improve protein translation accuracy. Q3 progress: both molecules appear to work indirectly; we are now identifying which pathways they target.
A novel neurodegeneration therapy -- sourced → vetted → funded → executing onchain. @Transfidelity_ is a DeSci project through and through, capturing what is possible when scientific talent meets onchain infrastructure.
1
1
4
Three facts about translation fidelity: ➤ Your cells make billions of proteins daily with ~1 error per 10,000 amino acids ➤ Error rates increase with aging and neurodegenerative disease ➤ Accumulated errors disrupt cellular function Explore #FIDEL: https://t.co/nbf4YRjaUp
4
6
24
Follow the Cerebrum DAO portfolio on X! 🔬 @Transfidelity_ - Protein translation accuracy ⚡ @FissionBioDeSci - Mitochondrial dysfunction therapeutics 🌿 @Neuron_Percepta - Brain health supplement 🧠 @NEURONGale - Neuroinflammation research (coming soon)
8
10
35
A successful townhall from the @Cerebrum_DAO team. Watch the recording here. Covering updates across Transfidelity, @FissionBioDeSci, @NEURONGale, and @Neuron_Percept, with some exciting developments incoming through Q4 and into 2026.
CerebrumDAO Quarterly AMA Townhall Q3/2025
2
3
14
A reminder about our Quarterly AMA Townhall for Q3/2025 tomorrow, October 24th, at 5:00 PM CET. We'll discuss updates, progress across our portfolio companies, science, and more. Ask us questions and get involved! Register here:
luma.com
Meet the Team behind CerebrumDAO 🗓️ October 24th · 5:00 PM CET (Berlin) Join us with a live conversation with the CerebrumDAO team. Hear about all our…
7
6
27
Yes - DeSci enables pragmatic, fast-moving, decentralized science. It's absolutely ideal for the type of early-stage research that can lead to huge outcomes across not just a singular disease but a whole spectrum.
This is why I love DeSci 🧬 Jan ‘24: I tell Edward Anderton I’m sourcing for VitaDAO. He mentions a project at Apollo Ventures, that is too early of them. Risky? Yes. But if Rashid & Dimitri are right… this could change how we treat chronic disease. At @vitadao & @Molecule_dao
2
2
9
A: Because cellular quality control systems decline with age and in disease conditions. When misfolded proteins accumulate faster than cells can clear them, they form aggregates that disrupt neuronal function. Our compounds target the root by improving translation fidelity.
0
3
6
Join @Cerebrum_DAO's Q3 townhall for updates and progress from the team! Plus details on what's coming in Q4 and beyond.
Cerebrum DAO Quarterly AMA Townhall Q3/2025 is here! Join us on a live conversation with our team. Hear about all our updates, portfolio companies, science and more. Ask us questions and get involved. 🗓️ October 24th at 5:00 PM CET 🔗 RSVP here:
0
0
4